Total Payments
$162,290
2024 Payments
$25,279
Companies
13
Transactions
103
Medicare Patients
344
Medicare Billing
$72,557
Payment Breakdown by Category
Consulting$84,335 (52.0%)
Travel$37,603 (23.2%)
Research$25,330 (15.6%)
Other$12,927 (8.0%)
Food & Beverage$2,095 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $84,335 | 22 | 52.0% |
| Travel and Lodging | $37,603 | 24 | 23.2% |
| Unspecified | $25,330 | 20 | 15.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $10,750 | 5 | 6.6% |
| Food and Beverage | $2,095 | 30 | 1.3% |
| Honoraria | $1,200 | 1 | 0.7% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $977.33 | 1 | 0.6% |
Payments by Type
General
$136,960
83 transactions
Research
$25,330
20 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Napo Pharmaceuticals Inc | $56,852 | 26 | $0 (2024) |
| PFIZER INC. | $51,738 | 28 | $0 (2024) |
| Helsinn Healthcare SA | $18,058 | 11 | $0 (2020) |
| Heron Therapeutics, Inc. | $13,564 | 7 | $0 (2019) |
| Helsinn Therapeutics (U.S.), Inc. | $8,744 | 12 | $0 (2017) |
| Merck Sharp & Dohme Corporation | $7,702 | 9 | $0 (2017) |
| Eisai Inc. | $3,025 | 1 | $0 (2017) |
| Veloxis Pharmaceuticals, Inc. | $1,150 | 1 | $0 (2021) |
| Medtronic USA, Inc. | $977.33 | 1 | $0 (2017) |
| Immunocore Limited | $221.46 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $25,279 | 20 | PFIZER INC. ($12,780) |
| 2023 | $19,374 | 11 | Napo Pharmaceuticals Inc ($13,477) |
| 2022 | $41,456 | 17 | PFIZER INC. ($28,229) |
| 2021 | $12,090 | 6 | Napo Pharmaceuticals Inc ($10,000) |
| 2020 | $7,050 | 2 | Helsinn Healthcare SA ($6,300) |
| 2019 | $13,042 | 5 | Heron Therapeutics, Inc. ($6,761) |
| 2018 | $6,804 | 4 | Heron Therapeutics, Inc. ($6,804) |
| 2017 | $37,196 | 38 | Helsinn Healthcare SA ($11,758) |
All Payment Transactions
103 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | PFIZER INC. | — | — | In-kind items and services | $780.00 | Research |
| Study: NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM | ||||||
| 12/17/2024 | Napo Pharmaceuticals Inc | Mytesi (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Infectious Disease | ||||||
| 12/06/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $26.25 | General |
| Category: Oncology | ||||||
| 10/31/2024 | PFIZER INC. | — | — | In-kind items and services | $620.00 | Research |
| Study: NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM | ||||||
| 10/31/2024 | PFIZER INC. | — | — | In-kind items and services | $620.00 | Research |
| Study: NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM | ||||||
| 10/10/2024 | PFIZER INC. | — | — | In-kind items and services | $3,200.00 | Research |
| Study: NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM | ||||||
| 09/25/2024 | Immunocore Limited | KIMMTRAK (Drug) | Food and Beverage | In-kind items and services | $27.71 | General |
| Category: Oncology | ||||||
| 09/17/2024 | Immunocore Limited | KIMMTRAK (Drug) | Food and Beverage | In-kind items and services | $118.75 | General |
| Category: Oncology | ||||||
| 09/10/2024 | PFIZER INC. | — | — | In-kind items and services | $1,820.00 | Research |
| Study: NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM | ||||||
| 08/14/2024 | Immunocore Limited | — | Food and Beverage | In-kind items and services | $75.00 | General |
| 07/26/2024 | PFIZER INC. | — | — | In-kind items and services | $3,200.00 | Research |
| Study: PONSEGROMAB CLINICAL PUBLICATION PROGRAM | ||||||
| 07/02/2024 | Napo Pharmaceuticals Inc | Mytesi (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Infectious Disease | ||||||
| 06/03/2024 | PFIZER INC. | — | — | In-kind items and services | $940.00 | Research |
| Study: PF06946860 CLINICAL PUBLICATION PROGRAM | ||||||
| 06/03/2024 | Napo Pharmaceuticals Inc | Mytesi (Drug) | Food and Beverage | Cash or cash equivalent | $77.10 | General |
| Category: Infectious Disease | ||||||
| 06/01/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $174.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 05/07/2024 | PFIZER INC. | — | — | In-kind items and services | $940.00 | Research |
| Study: NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM | ||||||
| 05/07/2024 | PFIZER INC. | — | — | In-kind items and services | $330.00 | Research |
| Study: PF06946860 CLINICAL PUBLICATION PROGRAM | ||||||
| 04/02/2024 | Napo Pharmaceuticals Inc | Mytesi (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Infectious Disease | ||||||
| 02/06/2024 | PFIZER INC. | — | — | In-kind items and services | $330.00 | Research |
| Study: PF06946860 MULTI PRODUCT CLINICAL PUBLICATION PROGRAM | ||||||
| 01/10/2024 | Napo Pharmaceuticals Inc | Mytesi (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Infectious Disease | ||||||
| 10/04/2023 | Napo Pharmaceuticals Inc | Mytesi (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Infectious Disease | ||||||
| 09/05/2023 | PFIZER INC. | — | — | In-kind items and services | $3,200.00 | Research |
| Study: NO PRODUCT CLINICAL PUBLICATION PROGRAM | ||||||
| 06/30/2023 | PFIZER INC. | — | — | In-kind items and services | $1,400.00 | Research |
| Study: PF06946860 CLINICAL PUBLICATION PROGRAM | ||||||
| 06/28/2023 | Napo Pharmaceuticals Inc | Mytesi (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Infectious Disease | ||||||
| 06/04/2023 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $27.02 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $7,980 | 6 |
| CACHEXIA CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $5,740 | 5 |
| PF06946860 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,610 | 4 |
| NO PRODUCT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,530 | 2 |
| PONSEGROMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| MULTI PRODUCT PF06946860 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| PF06946860 MULTI PRODUCT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 55 | 107 | $43,499 | $11,333 |
| 2022 | 3 | 73 | 113 | $42,899 | $12,480 |
| 2021 | 2 | 72 | 118 | $62,352 | $15,630 |
| 2020 | 5 | 144 | 315 | $151,949 | $33,114 |
Total Patients
344
Total Services
653
Medicare Billing
$72,557
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 31 | 74 | $31,153 | $8,049 | 25.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 12 | 12 | $6,264 | $1,728 | 27.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 12 | 21 | $6,082 | $1,556 | 25.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 32 | 66 | $25,987 | $7,623 | 29.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 21 | 21 | $9,945 | $2,955 | 29.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 20 | 26 | $6,967 | $1,902 | 27.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 41 | 83 | $44,400 | $11,197 | 25.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 18 | 18 | $9,498 | $2,684 | 28.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 13 | 17 | $8,454 | $1,749 | 20.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 28 | 95 | $56,931 | $12,147 | 21.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 31 | 67 | $31,376 | $6,427 | 20.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 24 | 62 | $25,980 | $5,617 | 21.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 21 | 21 | $17,138 | $3,700 | 21.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 13 | 21 | $9,393 | $2,034 | 21.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 15 | 28 | $4,960 | $1,863 | 37.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 12 | 21 | $6,171 | $1,326 | 21.5% |
About Dr. Eric Roeland, MD
Dr. Eric Roeland, MD is a Hospice and Palliative Medicine healthcare provider based in Portland, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/19/2007. The National Provider Identifier (NPI) number assigned to this provider is 1194909630.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Roeland, MD has received a total of $162,290 in payments from pharmaceutical and medical device companies, with $25,279 received in 2024. These payments were reported across 103 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($84,335).
As a Medicare-enrolled provider, Roeland has provided services to 344 Medicare beneficiaries, totaling 653 services with total Medicare billing of $72,557. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Hospice and Palliative Medicine
- Other Specialties Hematology & Oncology, Medical Oncology
- Location Portland, OR
- Active Since 12/19/2007
- Last Updated 04/13/2023
- Taxonomy Code 207RH0002X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1194909630
Products in Payments
- Mytesi (Drug) $56,852
- CINVANTI (Drug) $13,564
- NETUPITANT (Drug) $11,758
- Aloxi (Drug) $3,025
- Envarsus (Drug) $1,150
- SYNCHROMED (Device) $977.33
- CABOMETYX (Drug) $174.00
- KIMMTRAK (Drug) $146.46
- VARUBI (Drug) $38.87
- FOTIVDA (Drug) $26.25
- ZEJULA (Drug) $19.14
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hospice and Palliative Medicine Doctors in Portland
Leila August, Md, MD
Hospice and Palliative Medicine — Payments: $904.22
Hospice and Palliative Medicine $904.22
Dr. Rebecca Hutchinson, Md, MD
Hospice and Palliative Medicine — Payments: $800.00
Hospice and Palliative Medicine $800.00
Diana Zellner, D.o, D.O
Hospice and Palliative Medicine — Payments: $770.79
Hospice and Palliative Medicine $770.79
Andrea Nagengast, M.d, M.D
Hospice and Palliative Medicine — Payments: $172.09
Hospice and Palliative Medicine $172.09
Laura Director, Md, MD
Hospice and Palliative Medicine — Payments: $141.94
Hospice and Palliative Medicine $141.94
Rebecca Armendariz, Md, MD
Hospice and Palliative Medicine — Payments: $125.87
Hospice and Palliative Medicine $125.87